The Cannabinoid Product Board (CPB) is the result of the Cannabinoid Research Act, (H.B. 130) that was passed and was signed into law during the 2017 Utah General Legislative Session. During the 2018 Utah General Legislative Session, amendments (H.B. 25) were made to Cannabinoid Research Act as follows:
The Cannabinoid Research Act directs the Utah Department of Health (UDOH) to form and facilitate the CPB. As stated in the legislation, the purpose of the CPB is to review available research related to the human use of cannabinoid products. Specifically, the CPB evaluates the safety and efficacy of cannabinoid products and expanded cannabinoid products in terms of: 1) medical conditions that respond to cannabinoid products; 2) dosage amounts and their medical forms; and 3) interactions between cannabinoid products, expanded cannabinoid products, and other treatments. The CPB may only review research that has been approved by an Institutional Review Board, or approved/conducted by the federal government.
From this research, the CPB is directed to develop prescribing guidelines that may potentially be used by qualified medical providers recommending cannabinoid products to their patients. The CPB is directed to report the findings of their evaluation in writing to the Health and Human Services Interim Committee before November 1st of each year.